Abingdon Health PLC DeepVerge Testing Services Framework Agreement

TIDMABDX

Abingdon Health PLC

30 May 2022

Abingdon Health plc

("Abingdon" or the "Company")

DeepVerge Testing Services Framework Agreement

York, U.K. 30 May 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that it has signed a Testing Services Framework Agreement ("Agreement") with DeepVerge plc ("DeepVerge"), for the development and manufacture of a range of lateral flow tests ("LFTs") for DeepVerge's Modern Water and Life Science divisions.

DeepVerge (AIM: DVRG) is an environmental and life science group that develops and applies AI and IoT technology for the analysis and identification of bacteria, viruses and toxins. The agreement follows on from the strategic collaboration announcement made on 29 March 2022.

In the first instance Abingdon and DeepVerge will work on the development of LFT devices for DeepVerge's Modern Water division to detect dangerous pathogens and chemicals in household drinking and wastewater, as well as Environmental LFT tests covering acrylamide, microcystins, and algae. In due course, Abingdon and DeepVerge will also collaborate on the development of new lateral flow tests to be added to DeepVerge's life science home test portfolio, including hormone analysis related to menopause and associated skin changes and other health markers. DeepVerge will fund the development cost of the projects being undertaken and Abingdon will be exclusive manufacturer of the products developed and subsequently transferred into manufacturing.

Gerard Brandon, CEO of DeepVerge plc, commented:

"Leveraging the skillsets between DeepVerge and Abingdon to produce a range of new LFT tests, in such a short period of time, for the environmental and human health sectors is an example of the creative and adaptable skillsets that exist within the UK diagnostics industry. DeepVerge Group are looking forward to add these innovative new LFT units, produced entirely in the UK, to our 60+ country distribution channels in early 2023.

Chris Yates, CEO of Abingdon Health plc, commented:

"We are pleased to have signed this commercial agreement with DeepVerge. This strategic partnership will allow both companies to build a long-term collaboration to enable DeepVerge to leverage Abingdon's lateral flow development and manufacturing engine to launch a range of innovate tests into its core markets. This agreement underlines Abingdon's reputation as a knowledge leader and expert in the rapidly growing lateral flow testing market".

Enquiries:

 
 Abingdon Health plc                                www.abingdonhealth.com/investors/ 
 Chris Yates, Chief Executive Officer                                 Via Walbrook PR 
 Melanie Ross , Chief Financial Officer 
 Dr Chris Hand, Non-Executive Chairman 
 
 Singer Capital Markets (Sole Broker and                     Tel: [phone] 
  Nominated Adviser) 
 Peter Steel, Alex Bond (Corporate Finance) 
 Tom Salvesen (Corporate Broking) 
 
 Walbrook PR Limited              Tel: [phone] or [e-mail] 
 Paul McManus / Phillip                    Mob: [phone] 
  Marriage                                                                        082 
 Alice Woodings                                              Mob: [phone] 
 
 

About Abingdon Health plc

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx(R) , a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABKLLLLELZBBV

(END) Dow Jones Newswires

May 30, 2022 02:01 ET (06:01 GMT)